Disclosure of material event

01.06.2022 Read More

Disclosure of material event – Audio recording of Investors/Analysts meet

28.05.2022 Read More

Q4 FY22 Investor Presentation

27.05.2022 Read More

Recommendation of Final Dividend for FY 2021-22

27.05.2022 Read More

Q4 FY22 Press Release

26.05.2022 Read More

Q4 FY22 Results Sheet

26.05.2022 Read More

Disclosure of material event – Update on Assignment of Trademark for Azmarda® indicated for heart failure patients with reduced ejection fraction (HfrEF) from Novartis AG, Switzerland for India

13.04.2022 Read More

Assignment of Trademark for Azmarda® from Novartis AG, Switzerland for India

01.04.2022 Read More

Disclosure of material event – Resignation of Director

14.03.2022 Read More

Intimation of record date for Interim Dividend

14.02.2022 Read More

Declaration of Interim Dividend for FY 2021-22

14.02.2022 Read More

Q3 FY22 Press Release

14.02.2022 Read More

Q3 FY22 Investor Presentation

14.02.2022 Read More

Q3 FY22 Results Sheet

14.02.2022 Read More

Schedule of Investors /Analysts’ call with Management on 15.02.2022 and Registration Log-in details.

08.02.2022 Read More

Investor presentation in relation to Acquisition of Brands and Related Assets from Sanzyme Private Limited- 27.01.2022

27.01.2022 Read More

Disclosure of material event – Resignation of Director

27.01.2022 Read More

Press Release in relation to Acquisition of Brands and Related Assets from Sanzyme Private Limited

27.01.2022 Read More

Disclosure of material event – Acquisition of Brands and Related Assets from Sanzyme Private Limited

27.01.2022 Read More

Schedule of Investors / Analysts’ call with Management on 27.01.2022 and Registration Log-in details for the same

26.01.2022 Read More

Press Release regarding the launch of Molupiravir for the Indian market

29.12.2021 Read More